[go: up one dir, main page]

DE60214355D1 - Exemestan zur behandlung von hormonabhängigen störungen - Google Patents

Exemestan zur behandlung von hormonabhängigen störungen

Info

Publication number
DE60214355D1
DE60214355D1 DE60214355T DE60214355T DE60214355D1 DE 60214355 D1 DE60214355 D1 DE 60214355D1 DE 60214355 T DE60214355 T DE 60214355T DE 60214355 T DE60214355 T DE 60214355T DE 60214355 D1 DE60214355 D1 DE 60214355D1
Authority
DE
Germany
Prior art keywords
exemestan
hormone
treatment
related disorder
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60214355T
Other languages
English (en)
Other versions
DE60214355T2 (de
Inventor
Salle Enrico Di
Gabriella Piscitelli
Giorgio Massimini
Dinesh Purandare
Hendrik Dekoning
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Pharmacia and Upjohn Co LLC
Original Assignee
Pfizer Italia SRL
Pharmacia and Upjohn Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Italia SRL, Pharmacia and Upjohn Co LLC filed Critical Pfizer Italia SRL
Publication of DE60214355D1 publication Critical patent/DE60214355D1/de
Application granted granted Critical
Publication of DE60214355T2 publication Critical patent/DE60214355T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
DE60214355T 2001-01-26 2002-01-18 Exemestan zur behandlung von hormonabhängigen störungen Expired - Fee Related DE60214355T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77091101A 2001-01-26 2001-01-26
US770911 2001-01-26
PCT/EP2002/000638 WO2002072106A2 (en) 2001-01-26 2002-01-18 Combined method for treating hormono-dependent disorders with exemestane

Publications (2)

Publication Number Publication Date
DE60214355D1 true DE60214355D1 (de) 2006-10-12
DE60214355T2 DE60214355T2 (de) 2007-08-30

Family

ID=25090093

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60214355T Expired - Fee Related DE60214355T2 (de) 2001-01-26 2002-01-18 Exemestan zur behandlung von hormonabhängigen störungen

Country Status (12)

Country Link
EP (1) EP1377298B1 (de)
JP (1) JP2004519490A (de)
AR (1) AR032268A1 (de)
AT (1) ATE337787T1 (de)
CA (1) CA2434611A1 (de)
DE (1) DE60214355T2 (de)
DK (1) DK1377298T3 (de)
ES (1) ES2269682T3 (de)
MX (1) MXPA03006607A (de)
PE (1) PE20020843A1 (de)
PT (1) PT1377298E (de)
WO (1) WO2002072106A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040053900A1 (en) * 1998-12-23 2004-03-18 Pharmacia Corporation Method of using a COX-2 inhibitor and an aromatase inhibitor as a combination therapy
WO2003017973A1 (en) * 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. A method of treating benign gynaecological disorders and a drug delivery vehicle for use in such a method
GB0302572D0 (en) 2003-02-05 2003-03-12 Astrazeneca Ab Method of treatment
RU2227035C1 (ru) * 2003-02-05 2004-04-20 Павловский Алексей Васильевич Состав для профилактики и лечения фиброзно-кистозной мастопатии
EP1638573A4 (de) * 2003-06-20 2009-12-02 Merck & Co Inc Verwendung von selektiven cyclooxygenase-2-hemmern zur behandlung von endometriose
EP1951242A2 (de) * 2005-11-22 2008-08-06 Incyte Corporation Kombinationstherapie zur behandlung von krebs
KR20080112285A (ko) 2006-03-28 2008-12-24 자블린 파머슈티칼스 인코포레이티드 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형
WO2008019048A1 (en) * 2006-08-04 2008-02-14 Meditrina Pharmaceuticals Use of aromatase inhibitors for thining the endometrium or treating menorrhagia
RU2357733C1 (ru) * 2008-03-04 2009-06-10 Ольга Анатольевна Тихоновская Способ лечения функциональных кист яичников
CN101717393A (zh) * 2009-12-01 2010-06-02 陈依军 环己基2,5-二取代苯基醚的衍生物及其应用
DE102010003494A1 (de) * 2010-03-31 2011-10-06 Bayer Schering Pharma Aktiengesellschaft Parenterales Abgabesystem, das Aromatasehemmer und Gestagene freisetzt, für die Behandlung von Endometriose
AU2011264858B2 (en) 2010-06-10 2016-04-21 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
US9193714B2 (en) 2011-12-14 2015-11-24 Seragon Pharmaceuticals, Inc. Fluorinated estrogen receptor modulators and uses thereof
RS62591B1 (sr) 2013-09-24 2021-12-31 Fujifilm Corp Novo jedinjenje koje sadrži azot ili njegova so ili njihov kompleks sa metalom
JP2019500355A (ja) 2015-12-30 2019-01-10 セントルイス ユニバーシティ 汎インテグリンアンタゴニストとしてのメタ−アザ環式アミノ安息香酸誘導体
CN113712974A (zh) * 2021-08-20 2021-11-30 南京大学 阿司匹林在制备治疗子宫内膜增生药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8517360D0 (en) * 1985-07-09 1985-08-14 Erba Farmitalia Substituted androsta-1,4-diene-3,17-diones
GB8617107D0 (en) * 1986-07-14 1986-08-20 Erba Farmitalia 6-/7-methylenandrosta-1 4-diene-3 17-dione derivatives
KR950701341A (ko) * 1993-02-18 1995-03-23 비토리노 페라리오 불소화된 4-아미노안드로스타디에논 유도체 및 이들의 제조방법(Fluorinated 4-aminoandrostadienone derivatives and process for their preparation)
GB9313420D0 (en) * 1993-06-29 1993-08-11 Erba Carlo Spa Fluorinated 6-methylenandrosta-1,4-dien-3-one-derivatives and process for their preparations
BR9916518A (pt) * 1998-12-23 2002-01-29 Searle & Co Método para tratar ou prevenir um distúrbio de neoplasia em um mamìfero em necessidade de tal tratamento ou prevenção, e, combinação compreendendo um inibidor de ciclooxigenase-2 e um ou mais agentes anti-neoplásticos
AU784617B2 (en) * 2000-05-15 2006-05-18 Pharmacia & Upjohn Company Aromatase inhibitors and monoclonal anti-HER2 antibodies as antitumors agents
NZ524104A (en) * 2000-09-08 2004-12-24 Pharmacia Italia S Exemestane as chemopreventing agent

Also Published As

Publication number Publication date
CA2434611A1 (en) 2002-09-19
WO2002072106A2 (en) 2002-09-19
PT1377298E (pt) 2006-12-29
PE20020843A1 (es) 2002-09-25
WO2002072106A3 (en) 2003-10-30
ES2269682T3 (es) 2007-04-01
AR032268A1 (es) 2003-10-29
ATE337787T1 (de) 2006-09-15
EP1377298A2 (de) 2004-01-07
EP1377298B1 (de) 2006-08-30
MXPA03006607A (es) 2003-09-22
JP2004519490A (ja) 2004-07-02
DK1377298T3 (da) 2007-01-02
DE60214355T2 (de) 2007-08-30

Similar Documents

Publication Publication Date Title
ATE451921T1 (de) Phenylindole zur behandlung von hiv
DE50009504D1 (de) Verwendung von retigabin zur behandlung von neuropathischen schmerzen
DE60113496D1 (de) Verwendung von Glycyrrhizin zur Behandlung von Mastitis.
ATE358669T1 (de) Pyrazolderivate zur behandlung von hiv
EP1534074A4 (de) Kombinationstherapie zur behandlung von fettleibigkeit
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
ATE410430T1 (de) 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
DE10082139T1 (de) Zusammensetzung zur Behandlung von Reibungspaaren
DE60019158D1 (de) Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE69925865D1 (de) 4-(aminomethyl)-piperidinbenzamide zur behandlung von gastrointestinalen störungen
DE60214355D1 (de) Exemestan zur behandlung von hormonabhängigen störungen
DE60229959D1 (de) Kombinationstherapie zur behandlung von krebs
ATE279386T1 (de) Retinoide zur behandlung von emphysem
DE502004010131D1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
DE60238765D1 (de) Carbamatverbindungen zur behandlung von schmerz
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
ATE273276T1 (de) Cyclobutendion-derivate zur behandlung von artherosclerose
DE60223718D1 (de) Verwendung von norepinephrin wiederaufnahmehemmern zur behandlung von kognitiven störungen
DE60308045D1 (de) Pflanzenextrakte aus argyrolobium roseum zur behandlung von diabetes
DE60021252D1 (de) Antikonvulsiva zur behandlung von autismus
DE60223707D1 (de) Calcium-l-threonat zur behandlung von knochenfrakturen
DE60217653D1 (de) Verwendung von melatonin zur behandlung der mit konzentrationsschwäche einhergehenden hyperaktivität
DE50212649D1 (de) Verwendung von desoxypeganin zur behandlung der klinischen depression

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee